title: The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
abstract: Latest study showed that a novel translocation between programmed cell death ligand 1 (PD-L1) (cluster of differentiation 274) and TP63 (tumor protein 63) can be found in diffuse large B-cell lymphoma (DLBCL), resulting in their conjunct overexpression in tumor cells at RNA level. However, the expressed pattern of these 2 genes at protein level in DLBCL remains largely unknown, and the clinical relevance of PD-L1 and TP63 expression in DLBCL are also unclear.Tumor tissues from 76 Chinese DLBCL patients were immunostained for programmed cell death 1 (PD-1), PD-L1, and TP63 using the EnVision system. Clinical relevance of PD-1, PD-L1, and TP63 in 74 DLBCL were analyzed by chi-square test, the Kaplan-Meier curves with log rank test, and Cox's proportional hazards regression model.PD-1 was mainly expressed in tumor-infiltrating lymphocytes (TILs) of 39.5% patients. PD-L1 was expressed in tumor cells of 26.3% patients, and TP63 was immunostained in nucleoli of tumor cells of 31.6% cases. PD-1 expression was significantly associated with the patients' gender and B symptoms (P = 0.032, P = 0.026). DLBCL with PD-L1 or TP63 expression in tumor cells showed low International Prognostic Index (IPI) score (P = 0.007, P = 0.009). PD-1 TILs was related to prolonged overall survival rate (OS) of DLBCL patients (P = 0.02), whereas PD-L1 expression was associated with worse clinical outcome of patients (P = 0.049). Immunoreactivity of TP63 was not correlated with patients' survival time. Besides, PD-1 expression, patients' age, Ann Arbor stage, and IPI score were significant prognostic markers for OS, but PD-L1 and TP63 had no prognostic significance.PD-1, PD-L1, and TP63 are frequently expressed in DLBCL. PD-1/PD-L1/TP63 blockade may be a potential therapeutic strategy for some patients.
authors.affiliation: Department of Hematology Deparment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN Department of Laboratory, Shanghai Zhongliu Hospital, Shanghai Fudan University School of Medicine, Shanghai, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Fang
authors.forename: Bing
authors.initials: B
authors.lastname: Xiu
authors.forename: Zhizhang
authors.initials: Z
authors.lastname: Yang
authors.forename: Weizhe
authors.initials: W
authors.lastname: Qiu
authors.forename: Long
authors.initials: L
authors.lastname: Zhang
authors.forename: Suxia
authors.initials: S
authors.lastname: Zhang
authors.forename: Yunjin
authors.initials: Y
authors.lastname: Wu
authors.forename: Xuyou
authors.initials: X
authors.lastname: Zhu
authors.forename: Xue
authors.initials: X
authors.lastname: Chen
authors.forename: Suhong
authors.initials: S
authors.lastname: Xie
authors.forename: Xianghua
authors.initials: X
authors.lastname: Yi
authors.forename: Aibin
authors.initials: A
authors.lastname: Liang
authors.forename: Yu
authors.initials: Y
authors.lastname: Zeng
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000235:genetics; D060890:B7-H1 Antigen / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000235:genetics; D016009:Chi-Square Distribution; D002681:China; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*; D016016:Proportional Hazards Models; D012720:Severity of Illness Index; D015996:Survival Rate; D014157:Transcription Factors / Q000378:metabolism*; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C115051:TP63 protein, human; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins